Carregant...
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Although systemic therapy for patients with metastatic renal cell carcinoma (mRCC) was once limited to the cytokines interleukin-2 and interferon (IFN)-α, in recent years several targeted therapies have become available for first- and second-line use. These include sorafenib, sunitinib, bevacizumab...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AlphaMed Press
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3868199/ https://ncbi.nlm.nih.gov/pubmed/21346036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-S2-14 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|